Renhuang Pharmaceuticals, Inc. was founded in 1996 in Harbin, Heilongjiang province in Northeast China. In September 2006, the Company became a public company in the United States through a reverse merger and is currently traded on OTCBB (RHGP.OB).

Renhuang Pharmaceuticals is an integrated developer, manufacturer and distributor of a broad line of high-quality nutraceutical, biopharmaceutical, and natural medicinal products.  The Company provides three major product lines including the Acanthopanax-based natural medicinal products, biopharmaceutical products, and Traditional Chinese Medicines, currently representing roughly 50%, 20%, and 30% of total revenues, respectively.  Renhuang?s key product line is an Acanthopanax-based product series, a natural medicine effective in treating depression and melancholy, and provides numerous other health benefits.  By controlling an estimated 70% of China?s natural resource of Acanthopanax (also known as Siberian Ginseng), the Company possesses a unique competitive edge and, therefore, occupies a dominant market position in Acanthopanax-based medicinal and nutraceutical products.

Renhuang distributes its products through a multi-layered sales network of over 2,000 sales agents organized under 70 sales centers across 24 districts that cover over 50% of greater China.  Its products are not only sold nationwide but also exported to Russia and Southeast Asia.